Jean Jacques Bienaime Acquires 7,000 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 7,000 shares of the company’s stock in a transaction on Monday, March 24th. The stock was bought at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the purchase, the director now owns 23,615 shares of the company’s stock, valued at approximately $193,879.15. The trade was a 42.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Immunome Stock Performance

Shares of IMNM opened at $7.09 on Thursday. Immunome, Inc. has a 52-week low of $6.94 and a 52-week high of $26.70. The stock’s 50-day simple moving average is $9.61 and its 200 day simple moving average is $11.41. The stock has a market capitalization of $616.48 million, a price-to-earnings ratio of -0.87 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. On average, research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Enavate Sciences GP LLC bought a new position in Immunome in the 4th quarter worth about $36,939,000. JPMorgan Chase & Co. grew its position in Immunome by 2,540.4% in the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock worth $6,888,000 after acquiring an additional 624,045 shares in the last quarter. Janus Henderson Group PLC increased its stake in Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Granahan Investment Management LLC purchased a new stake in Immunome during the fourth quarter valued at about $3,337,000. Finally, Renaissance Technologies LLC increased its position in shares of Immunome by 2,696.5% during the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock valued at $3,356,000 after purchasing an additional 304,700 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on IMNM shares. Guggenheim dropped their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target for the company. Stephens reissued an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $25.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.